Home

OrbiMed Israel GP Ltd.

CIK 1569590 · last filed 2026-04-09

OrbiMed Israel GP Ltd. is a corporate insider who has filed 17 SEC Form 4 insider transactions across 6 companies since 2017. The most recent filing shows the insider sold $5.4M of ACET on Apr 9, 2026. Across all open-market trades the lifetime net is −$47.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.57M

Companies

6

Total Filings

17

Lifetime Open-Market Net

-$47.47M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACET Director 78,499 $8.20 $643.7K -$5.40M 2 2026-04-09
BiomX Inc. (PHGE.WS) Delisted Director 2,813,489 $0.01 $24.8K $242.5K 3 2021-07-30
9 METERS BIOPHARMA, INC. (NMTR) Delisted Director 1,597 $0.07 $115 -$41.87M 6 2021-06-25
CMMB 10%+ Owner 644,544 $1.43 $921.7K $0 1 2021-03-18
Eledon Pharmaceuticals, Inc. (NVUS) Delisted Director 73,650 — — -$451.8K 2 2020-12-04
Eledon Pharmaceuticals, Inc. (TKAI) Delisted Director 2,537,110 — — $0 1 2017-05-11

Recent Filings

17 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-09 ACET Sell (S) −837,264 -$5.40M EDGAR
2026-04-07 ACET Notice (144) −64,242 -$413.1K EDGAR
2024-09-12 — Notice (144) −500,000 -$1.01M EDGAR
2021-07-30 BiomX Inc. (PHGE.WS) Delisted Buy (P) +1,000,000 $0 EDGAR
2021-06-25 9 METERS BIOPHARMA, INC. (NMTR) Delisted Sell (S) −34,301,562 -$41.87M EDGAR
2021-05-13 9 METERS BIOPHARMA, INC. (NMTR) Delisted Exer (X) +63,888 $41.7K EDGAR
2021-03-19 9 METERS BIOPHARMA, INC. (NMTR) Delisted Mixed +37,860,510 $0 EDGAR
2021-03-18 CMMB Grant (A) +576,340 $10.00M EDGAR
2020-12-04 Eledon Pharmaceuticals, Inc. (NVUS) Delisted Sell (S) −206,400 -$4.46M EDGAR
2020-11-03 9 METERS BIOPHARMA, INC. (NMTR) Delisted Other (J) +3,887,468 $0 EDGAR
Showing 1–10 of 17
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.